Hyperprolactinemia with aripiprazole: Understanding the paradox

Gayatri Saraf, Rishikesh V. Behere, Ganesan Venkatasubramanian, Naren P. Rao, Shivarama Varambally, B. N. Gangadhar

Research output: Contribution to journalArticlepeer-review

11 Citations (Scopus)


Aripiprazole, due to its partial agonist activity at the D2 receptors, is often recommended as the drug of choice in patients who develop antipsychotic-induced hyperprolactinemia. We report a case of a female patient who developed hyperprolactinemia while on treatment with aripiprazole. This partial D2 agonistic activity of aripiprazole could be dose related, and hence, at higher doses, aripiprazole by itself can have dopamine antagonistic properties and hence cause prolactin system abnormalities.

Original languageEnglish
JournalAmerican Journal of Therapeutics
Issue number3
Publication statusPublished - 01-01-2014
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Hyperprolactinemia with aripiprazole: Understanding the paradox'. Together they form a unique fingerprint.

Cite this